

## **SUPPLEMENTAL MATERIAL**

### **Pharmacokinetics and dialyzability of a single oral dose of amenamevir, an anti-herpes drug in hemodialysis patients**

Shuichi Tsuruoka<sup>1</sup>, Takamasa Endo<sup>2</sup>, Mizuna Seo<sup>2</sup>, Naoto Hashimoto<sup>3</sup>

<sup>1</sup> *Department of Nephrology, Nippon Medical School, Tokyo, Japan*

<sup>2</sup> *Clinical Development Department, Maruho Co., Ltd., Kyoto, Japan*

<sup>3</sup> *Drug Development Research Laboratory, Maruho Co., Ltd., Kyoto, Japan*

**Supplemental Table S1** List of the principal investigators and institutional review boards







**Supplemental Figure S1** Correlation between; (A) hemodialysis clearance of amenamevir (mL/min/m<sup>2</sup>) and normalized dialysis dose, (B) hemodialysis clearance of amenamevir (mL/min/m<sup>2</sup>) and serum albumin (g/dL), (C) elimination fraction of amenamevir (%) and normalized dialysis dose, (D) elimination fraction of amenamevir (%) and serum albumin (g/dL), (E) amount removed of amenamevir (μg) and normalized dialysis dose, (F) amount removed of amenamevir (μg) and serum albumin (g/dL)

**Supplemental Figure S2** Correlation between; (A) hemodialysis clearance of R5 (mL/min/m<sup>2</sup>) and normalized dialysis dose, (B) hemodialysis clearance of R5 (mL/min/m<sup>2</sup>) and serum albumin (g/dL), (C) elimination fraction of R5 (%) and normalized dialysis dose, (D) elimination fraction of R5 (%) and serum albumin (g/dL),







(E) amount removed of R5 ( $\mu\text{g}$ ) and normalized dialysis dose, (F) amount removed of R5 ( $\mu\text{g}$ ) and serum albumin ( $\text{g/dL}$ )

**Supplemental Table S1 List of the principal investigators and institutional review boards**

Principal investigator	Institution	Institutional review board	Reference number
Tomomasa Oguchi	Aizawa Hospital, Matsumoto, Nagano, Japan	Institutional Review Board of Aizawa Hospital	—
Tadashi Iitsuka	Ibaraki Seinan Medical Center Hospital, Sakaimachi, Ibaraki, Japan	Review Board of Human Rights and Ethics for Clinical Studies Institutional Review Board	2018052
Tokuro Kobayashi	Moriya Keiyu Hospital, Moriya, Ibaraki, Japan	Review Board of Human Rights and Ethics for Clinical Studies Institutional Review Board	2018052
Takashi Udagawa	Nippon Koukan Hospital, Kawasaki, Kanagawa, Japan	Institutional Review Board of Nippon Koukan Hospital	—
Katsushige Abe	Jinikai Hospital, Oita, Oita, Japan	Nihonbashi Sakura Clinic Institutional Review Board	—
Hidetoshi Yoshinaga	Social Medical Corporation the Chiyukai Foundation Fukuoka Wajiro Hospital, Fukuoka, Fukuoka, Japan	Nihonbashi Sakura Clinic Institutional Review Board	—



**Supplemental Figure S1**



**Supplemental Figure S2**